Heron Therapeutics (NASDAQ:HRTX – Get Free Report) will post its quarterly earnings results after the market closes on Tuesday, March 12th. Analysts expect Heron Therapeutics to post earnings of ($0.15) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.
Heron Therapeutics Trading Up 0.4 %
Shares of HRTX stock opened at $2.60 on Friday. The business’s 50-day moving average price is $2.40 and its 200-day moving average price is $1.61. Heron Therapeutics has a 12 month low of $0.50 and a 12 month high of $2.99. The firm has a market capitalization of $390.18 million, a price-to-earnings ratio of -2.71 and a beta of 1.68.
Analyst Ratings Changes
A number of analysts have recently commented on the company. StockNews.com raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Needham & Company LLC lowered their price objective on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, November 15th.
Hedge Funds Weigh In On Heron Therapeutics
A number of hedge funds have recently made changes to their positions in HRTX. Sei Investments Co. bought a new position in shares of Heron Therapeutics during the first quarter worth about $27,000. State of Wyoming bought a new stake in Heron Therapeutics in the second quarter worth approximately $28,000. Bayesian Capital Management LP bought a new stake in Heron Therapeutics in the fourth quarter worth approximately $35,000. Citigroup Inc. increased its holdings in Heron Therapeutics by 195.6% in the second quarter. Citigroup Inc. now owns 30,845 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 20,412 shares in the last quarter. Finally, Point72 Middle East FZE bought a new stake in Heron Therapeutics in the fourth quarter worth approximately $37,000. 81.77% of the stock is currently owned by institutional investors.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Read More
- Five stocks we like better than Heron Therapeutics
- Want to Profit on the Downtrend? Downtrends, Explained.
- MarketBeat Week in Review – 3/4 – 3/8
- How is Compound Interest Calculated?
- What is a Microcap Stock? Everything You Need to Know
- P/E Ratio Calculation: How to Assess Stocks
- How to Invest in Casino Stocks: Pros and Cons and More
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.